Table 2 Main demographic, clinical and serological characteristics of PCR+ groups

Patients [n (%)]

39

19

–

SARS-CoV-2 IgM+ cases [n (%)]

7 (17.9)

3 (15.8)

ns

SARS-CoV-2 IgG+ cases [n (%)]

33 (84.6)

16 (84.2)

ns

SARS-CoV-2 IgG RBD+ cases [n (%)]

25 (64.1)

10 (52.6)

ns

SARS-CoV-2 IgM [AU/mL]

12.99 ± 26.93

2.50 ± 3.26

0.0213

SARS-CoV-2 IgG [AU/mL]

543.2 ± 913,7

985.7 ± 990.3

ns

SARS-CoV-2 IgG RBD [AU/mL]

203.6 ± 344.1

617.1 ± 307.7

< 0.0001

Age [years]

60.9 ± 11.9

49.7 ± 15.8

0.0037

Gender—F/M [n]

28:11

11:8

ns

SARS-CoV-2 vaccinated pts. [n (%)]

17 (43.5%)

12 (63%)

ns

Chronic comorbidities

 Cardiovascular diseases [n (%)]

26 (66.7)

5 (26.3)

0.0483

  Primary cardiomyopathy

3 (7.7)

0 (0)

ns

  Ischemic cardiomyopathy

7 (17.9)

0 (0)

ns

  Hypertension

24 (61.5)

5 (26.3)

0.0075

  Cardiac arrhythmias

4 (10.3)

0 (0)

ns

  Congenital heart disease

0 (0)

0 (0)

ns

 Metabolic diseases [n (%)]

19 (48.7)

6 (31.6)

ns

  Diabetes mellitus type 2

6 (15.4)

1 (5.3)

ns

  Obesity

14 (3.9)

5 (26.3)

ns

 Respiratory diseases [n (%)]

2 (5.1)

1 (5.3)

ns

  Asthma

1 (2.6)

0 (0)

ns

  COPD

1 (2.6)

1 (5.3)

ns

 Renal diseases [n (%)]

2 (5.1)

1 (5.3)

ns